Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 16/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886856 | 0.88 | EGFR (0.40) | TLR8TLR7POLB | |
| SCHEMBL1095552 | 0.84 | TLR8 (0.49) | TLR8CRBNTLR7 | |
| SCHEMBL18759358 | 0.79 | TLR8 (0.35) | TLR8TLR7POLB | |
| SCHEMBL18297269 | 0.76 | TLR8 (0.49) | TLR8TLR7POLB | |
| SCHEMBL233868 | 0.74 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL233870 | 0.71 | TLR8 (0.36) | TLR8CRBNTLR7PLK1MKNK1 | |
| SCHEMBL1095204 | 0.70 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL1238259 | 0.70 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL1237644 | 0.68 | TLR8 (0.54) | TLR8TLR7 | |
| SCHEMBL1237420 | 0.67 | TLR8 (0.50) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180303845-A1 | USE OF TLR8 AGONISTS TO TREAT CANCER | VENTIRX PHARMACEUTICALS, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10016440-B2 | Methods of enhancing antibody-dependent cellular cytotoxicity | VENTIRX PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2560658-B1 | ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170027954-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20130236449-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120003213-A1 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity | VENTIRX PHARMACEUTICALS, INC. | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003213-A1 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity | GZMB, CD47, FCGR3B | TLR8 1934/4885CRBN 573/4885TLR7 2308/4885 |
| US-20180303845-A1 | USE OF TLR8 AGONISTS TO TREAT CANCER | TLR8, TLR1, TLR3 | TLR8 1/4885CRBN 4248/4885TLR7 5/4885 |
| US-20130236449-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | GZMB, CD47, FCGR3B | TLR8 1934/4885CRBN 573/4885TLR7 2308/4885 |
| US-20170027954-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | GZMB, CD47, FCGR3B | TLR8 1934/4885CRBN 573/4885TLR7 2308/4885 |
| US-10016440-B2 | Methods of enhancing antibody-dependent cellular cytotoxicity | GZMB, CD47, FCGR3B | TLR8 1934/4885CRBN 573/4885TLR7 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.